Skip to main content

Advertisement

Fig. 1 | Malaria Journal

Fig. 1

From: New developments in anti-malarial target candidate and product profiles

Fig. 1

The role of current and new medicines in driving the reduction of malaria to zero and maintaining elimination in countries ([3, 175] and ‘malERA Refresh’, manuscript submitted). Given that even the most advanced new blood schizonticides will not be approved into policy until the 2020s, much of the initial phase of reduction will be carried out using current medicines, continually optimized for deployment. Transmission blocking will be achieved by the use of insecticides and other vector control methods. As resistance develops there will be a need for new classes of medicines, ideally capable of shortening the treatment course and simplifying therapy (labelled here as SERC, but also including two- or even 3-day regimens). For countries in pre-elimination and elimination, new classes of chemoprotectants will be needed, and this need will arguably increase as the number of countries in pre-elimination increases

Back to article page